Faeth Therapeutics, Inc. Operating Income
Faeth Therapeutics, Inc. (FTH) reported Operating Income of -$18.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-04
- Faeth Therapeutics, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$18.39M.
- Faeth Therapeutics, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$170.63M.
- Faeth Therapeutics, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$4.96M.
- Faeth Therapeutics, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$4.85M.
- Faeth Therapeutics, Inc. operating income (loss) for fiscal 2025 was -$22.29M.
- Faeth Therapeutics, Inc. operating income (loss) for fiscal 2024 was -$32.61M.
- Faeth Therapeutics, Inc. operating income (loss) for fiscal 2023 was -$37.06M.
- Faeth Therapeutics, Inc. operating income (loss) for fiscal 2022 was -$50.19M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$18.39M 10-Q · filed 2026-08-04 | -$189.01M 10-Q · filed 2026-08-04 | -$193.97M derived: sum of 3 quarters · filed 2026-08-04 | -$198.82M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$170.63M 10-Q · filed 2026-05-15 | -$175.58M derived: sum of 2 quarters · filed 2026-05-15 | -$180.44M derived: sum of 3 quarters · filed 2026-05-15 | -$185.64M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$4.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$9.81M derived: sum of 2 quarters · filed 2026-03-30 | -$15.01M derived: sum of 3 quarters · filed 2026-08-04 | -$22.29M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$4.85M 10-Q · filed 2025-11-14 | -$10.06M derived: sum of 2 quarters · filed 2026-08-04 | -$17.33M 10-Q · filed 2025-11-14 | -$25.61M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$5.21M 10-Q · filed 2026-08-04 | -$12.48M 10-Q · filed 2026-08-04 | -$20.75M derived: sum of 3 quarters · filed 2026-08-04 | -$28.58M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$7.27M 10-Q · filed 2026-05-15 | -$15.55M derived: sum of 2 quarters · filed 2026-05-15 | -$23.37M derived: sum of 3 quarters · filed 2026-05-15 | -$31.16M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$8.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$16.10M derived: sum of 2 quarters · filed 2026-03-30 | -$23.88M derived: sum of 3 quarters · filed 2026-03-30 | -$32.61M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$7.82M 10-Q · filed 2025-11-14 | -$15.61M derived: sum of 2 quarters · filed 2025-11-14 | -$24.34M 10-Q · filed 2025-11-14 | -$32.48M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$7.79M 10-Q · filed 2025-08-05 | -$16.52M 10-Q · filed 2025-08-05 | -$24.66M derived: sum of 3 quarters · filed 2025-08-05 | -$32.40M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$8.73M 10-Q · filed 2025-05-06 | -$16.87M derived: sum of 2 quarters · filed 2025-05-06 | -$24.61M derived: sum of 3 quarters · filed 2025-05-06 | -$34.79M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$8.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$15.88M derived: sum of 2 quarters · filed 2025-03-28 | -$26.06M derived: sum of 3 quarters · filed 2025-03-28 | -$37.06M 10-K · filed 2025-03-28 |
| 2023-09-30 | -$7.74M 10-Q · filed 2024-11-14 | -$17.91M derived: sum of 2 quarters · filed 2024-11-14 | -$28.92M 10-Q · filed 2024-11-14 | -$41.97M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$10.18M 10-Q · filed 2024-08-06 | -$21.18M 10-Q · filed 2024-08-06 | -$34.23M derived: sum of 3 quarters · filed 2024-08-06 | -$48.17M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$11.01M 10-Q · filed 2024-05-09 | -$24.06M derived: sum of 2 quarters · filed 2024-05-09 | -$38.00M derived: sum of 3 quarters · filed 2024-05-09 | -$48.71M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$13.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$26.99M derived: sum of 2 quarters · filed 2024-02-29 | -$37.70M derived: sum of 3 quarters · filed 2024-02-29 | -$50.19M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$13.94M 10-Q · filed 2023-11-07 | -$24.65M derived: sum of 2 quarters · filed 2023-11-07 | -$37.14M 10-Q · filed 2023-11-07 | -$46.55M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$10.71M 10-Q · filed 2023-08-03 | -$23.20M 10-Q · filed 2023-08-03 | -$32.61M derived: sum of 3 quarters · filed 2023-08-03 | -$42.93M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$12.49M 10-Q · filed 2023-05-09 | -$21.90M derived: sum of 2 quarters · filed 2023-05-09 | -$32.22M derived: sum of 3 quarters · filed 2023-05-09 | -$42.00M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$9.41M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$19.73M derived: sum of 2 quarters · filed 2023-03-29 | -$29.51M derived: sum of 3 quarters · filed 2023-03-29 | -$37.48M 10-K · filed 2023-03-29 |
| 2021-09-30 | -$10.32M 10-Q · filed 2022-11-08 | -$20.10M derived: sum of 2 quarters · filed 2022-11-08 | -$28.07M 10-Q · filed 2022-11-08 | -$33.15M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$9.78M 10-Q · filed 2022-08-09 | -$17.75M 10-Q · filed 2022-08-09 | -$22.83M derived: sum of 3 quarters · filed 2022-08-09 | -$28.19M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$7.97M 10-Q · filed 2022-05-10 | -$13.05M derived: sum of 2 quarters · filed 2022-05-10 | -$18.41M derived: sum of 3 quarters · filed 2022-05-10 | -$23.32M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$5.08M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$10.44M derived: sum of 2 quarters · filed 2022-03-15 | -$15.35M derived: sum of 3 quarters · filed 2022-03-15 | -$19.45M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$5.36M 10-Q · filed 2021-11-10 | -$10.27M derived: sum of 2 quarters · filed 2021-11-10 | -$14.37M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$4.91M 10-Q · filed 2021-08-11 | -$9.01M 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | -$4.10M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |